The state-run Xinhua News Agency reported on the 31st, citing the state council’s announcement, that the National Drug Administration, which is in charge of drug approval in China, has conditionally approved a novel coronavirus infection (Corona 19) vaccine developed by the state-run pharmaceutical company Sinoparm. Synofarm announced the results of the phase 3 clinical trial of the vaccine the day before, and said that the preventive effect was 79.34% and the antibody positive rate was 99.52%, respectively. The preventive effect is about 15 percentage points lower than that of Pfizer-Bioentech developed in cooperation with the United States and Germany, or the United States’ Modena vaccine.
Synofam product is an inactivated vaccine that activates the immune system by inoculating the human body after killing the virus cultured in the laboratory with drugs. Unlike Pfizer/Bioentech and Modena of the United States, which injects genetic material, mRNA (messenger RNA), into the human body instead of the reduced toxicity coronavirus, and applies advanced technology to activate the immune system without risk of infection, Synofam vaccine is a long-standing traditional vaccine. Used technology.
Synoparm emphasized that its vaccine can be stored for a long time at room temperature and that the production cost is low. The State Council of China said the vaccine was in compliance with the standards of the World Health Organization (WHO) and its National Drug Administration. China is pushing for 50 million vaccinations by mid-February, when the population movement rapidly increases due to the Lunar New Year holidays.
Meanwhile, the New York Times (NYT) pointed out that “Sinopharm did not disclose detailed information on the size of the clinical trial or side effects,” and “It has increased the opacity of the vaccine by not answering many questions raised.” Citing Australian pediatrician Dr. Murdoch Kim Mulholland, “Chinese pharmaceutical companies provided less information on vaccines than in Russia.” NYT said, “China has five new coronavirus vaccines that have entered phase 3, which is the final stage of clinical trials, and has already produced millions of batches.”
Reporter Shin Kyungjin [email protected]